原发性肝内胆管癌的临床病理特征与外科策略

国际肿瘤学杂志››2015,Vol. 42››Issue (1): 60-63.doi:10.3760/cma.j.issn.1673-422X.2015.01.016

原发性肝内胆管癌的临床病理特征与外科策略

雷道雄, 王凤飚, 刘森

300140天津医科大学第四中心临床学院天津市第四中心医院肝胆外科

收稿日期:2014-06-10修回日期:2014-08-04出版日期:2015-01-08发布日期:2015-01-07
通讯作者:雷道雄 E-mail:daoxiong.lei@yahoo.com
基金资助:

天津市应用基础与前沿技术研究计划项目（14JCYBJC25900）

Clinical pathological features and surgical treatment of primary intrahepatic cholangiocarcinoma

Lei Daoxiong, Wang Fengbiao, Liu Sen

Fourth Center Clinical College, Tianjin Medical University, Department of Hepatobiliary Surgery, Tianjin Forth Central Hospital, Tianjin 300140, China

Received:2014-06-10Revised:2014-08-04Online:2015-01-08Published:2015-01-07
Contact:Lei Daoxiong E-mail:daoxiong.lei@yahoo.com

摘要/Abstract

摘要：原发性肝内胆管癌是成人肝脏内发生的第2大类原发性恶性肿瘤，全球范围内呈日益增多的趋势。病理学上以结节型多见，典型的组织学表现为管状腺癌。手术切除是其获得治愈的唯一有效方法，部分早期患者还可选择肝移植。对于不能切除的或术后复发的患者，可行射频消融、经肝动脉栓塞化疗或分子靶向治疗。

关键词:胆管,肝内,胆管肿瘤,病理学,临床,外科治法

Abstract:Primary intrahepatic cholangiocarcinoma (ICC) is the second frequent malignant tumor in adult liver, and appears an increasing tendency worldwide. Gross type is frequently massforming and a tubular adenocarcinoma is shown as the typical histopathological appearance. Surgical resection is the only curative treatment, and liver transplantation is selected for the patients with early ICC. Rediofrequency ablation, transcatheter arterial chemoembolization or molecular targeted therapies should be considered in the treatment of the unresectable or recurrent patients.

Key words:Bile ducts, intrahepatic,Bile duct neoplasms,Pathology, clinical,Surgical therapy

雷道雄, 王凤飚, 刘森. 原发性肝内胆管癌的临床病理特征与外科策略[J]. 国际肿瘤学杂志, 2015, 42(1): 60-63.

Lei Daoxiong, Wang Fengbiao, Liu Sen. Clinical pathological features and surgical treatment of primary intrahepatic cholangiocarcinoma[J]. Journal of International Oncology, 2015, 42(1): 60-63.

参考文献

［1］ Njei B. Intrahepatic cholangiacarcinoma: are we doing the right thing?［J］. Gastrointerst Cancer Res, 2014, 7(1): 1-3. ［2］朱珍, 丛文铭. 肝内胆管细胞癌的临床病理学观察［J］. 临床肝胆病杂志, 2013, 29(1): 42-44. ［3］ Konstadoulakis MM, Roayaie S, Gomatos IP, et al. Fifteenyear, singlecenter experience with the surgical management of intrahepatic cholangiocarcinoma: operative results and longterm outcome［J］. Surgery, 2008, 143(3): 366374. ［4］ Shimada M, Sugimoto K, Iwahashi S, et al. CD133 expression is a potential prognostic indicator in intrahepatic cholangiocarcinoma［J］. J Gastroenterol, 2010, 45(8): 896-902. ［5］ Edge SB, Compton CC. The American Joint Committee on Cancer: the 7th edition of the AJCC cancer staging manual and the future of TNM［J］. Ann Surg Oncol, 2010, 17(6): 14711474. ［6］ Bridgewater J, Galle PR, Khan SA, et al. Guidelines for the diagnosis and management of intrahepatic cholangiacarcinoma［J］. J Hepatol, 2014, 60(6): 1268-1289. ［7］ Brown KM, Parmar AD, Geller DA. Intrahepatic cholangiacarcinoma［J］. Surg Oncol Clin N Am, 2014, 23(2): 231-246. ［8］ Tan JC, Coburn NG, Baxter NN, et al. Surgical management of intrahepatic cholangiocarcinomaa populationbased study［J］. Ann Surg Oncol, 2008, 15(2): 600-608. ［9］ Uenishi T, Kubo S, Yamazaki O, et al. Indications for surgical treatment of intrahepatic cholangiocarcinoma with lymph node metastases［J］. J Hepatobiliary Pancreatic Surg, 2008, 15(4): 417-422. ［10］ Tamandl D, Herberger B, Gruenberger B, et al. Influence of hepatic resection margin on recurrence and survival in intrahepatic cholangiocarcinoma［J］. Ann Surg Oncol, 2008, 15(10): 2787-2794. ［11］ Ribero D, Pinna AD, Guglielmi A, et al. Surgical approach for longterm survival of patients with intrahepatic cholangiocarcinoma: a multiinstitutional analysis of 434 patients［J］. Arch Surg, 2012, 147(12): 1107-1113. ［12］ Endo I, Gonen M, Yopp AC, et al. Intrahepatic cholangiocarcinoma: rising frequency, improved survival, and determinants of outcome after resection［J］. Ann Surg, 2008, 248(1): 84-96. ［13］ Choi SB, Kim KS, Choi JY, et al. The prognosis and survival outcome of intrahepatic cholangiocarcinoma following surgical resection: association of lymph node metastasis and lymph node dissection with survival［J］. Ann Surg Oncol, 2009, 16(11): 3048-3056. ［14］ Hyder O, Hatzaras I, Sotiropoulos GC, et al. Recurrence after operative management of intrahepatic cholangiocarcinoma［J］. Surgery, 2013, 153(6): 811-818. ［15］ Fu BS, Zhang T, Li H, et al. The role of liver transplantation for intrahepatic cholangiocarcinoma: a singlecenter experience［J］. Eur Surg Res, 2011, 47(4): 218221. ［16］ Wolfe RA, Roys EC, Merion RM. Trends in organ donation and transplantation in the United States, 19992008［J］. Am J Transplant, 2010, 10(4): 961-972. ［17］ Hong JC, Jones CM, Duffy JP, et al. Comparative analysis of resection and liver transplantation for intrahepatic and hilar cholangiocarcinoma: a 24year experience in a single center［J］. Arch Surg, 2011, 146(6): 683-689. ［18］ Sapisochin G, Rodriguez de Lope C, Gastaca M, et al. "Very early" intrahepatic cholangiocarcinoma in cirrhotic patients: should liver transplantation be reconsidered in these patients?［J］. Am J transplant, 2014, 14(3): 660-667. ［19］ Gusani NJ, Balaa FK, Steel JL, et al. Treatment of unresectable cholangiocarcinoma with gemcitabinebased transcatheter arterial chemoembolization (TACE): a singleinstitution experience［J］. J Gastrointest Surg, 2008, 12(1): 129-137. ［20］ Jarnagin WR, Schwartz LH, Gultekin DH, et al. Regional chemotherapy for unresectable primary liver cancer: results of a phase Ⅱ clinical trial and assessment of DCEMRI as a biomarker of survival［J］. Ann Oncol, 2009, 20(9): 1589-1595. ［21］ Kiefer MV, Albert M, McNally M, et al. Chemoembolization of intrahepatic cholangiocarcinoma with cisplatinum, doxorubicin, mitomycin C, ethiodol, and polyvinyl alcohol: a 2center study［J］. Cancer, 2011, 117(7): 1498-1505. ［22］ Hoffmann RT, Paprottka PM, Schon A, et al. Transarterial hepatic yttrium90 radioembolization in patients with unresectable intrahepatic cholangiocarcinoma: factors associated with prolonged survival［J］. Cardiovasc Intervent Radiol, 2012, 35(1): 105-116. ［23］ Kim JH, Won HJ, Shin YM, et al. Radiofrequency ablation for the treatment of primary intrahepatic cholangiocarcinoma［J］. AJR Am J Roentgenol, 2011, 196(2): W205-209. ［24］ Fu Y, Yang W, Wu W, et al. Radiofrequency ablation in the management of unresectable intrahepatic cholangiocarcinoma［J］. J Vasc Intervent Radiol, 2012, 23(5): 642-649. ［25］ Sia D, Tovar V, Moeini A, et al. Intrahepatic cholangiocarcinoma: pathogenesis and rationale for molecular therapies［J］. Oncogene, 2013, 32(41): 4861-4870. ［26］ Bengala C, Bertolini F, Malavasi N, et al. Sorafenib in patients with advanced biliary tract carcinoma: a phase Ⅱ trial［J］. Br J Cancer, 2010, 102(1): 68-72. ［27］ Zhu AX, Meyerhardt JA, Blaszkowsky LS, et al. Efficacy and safety of gemcitabine, oxaliplatin, and bevacizumab in advanced biliarytract cancers and correlation of changes in 18fluorodeoxyglucose PET with clinical outcome: a phase 2 study［J］. Lancet Oncol, 2010, 11(1): 4854. ［28］ Gruenberger B, Schueller J, Heubrandtner U, et al. Cetuximab, gemcitabine, and oxaliplatin in patients with unresectable advanced or metastatic biliary tract cancer: a phase 2 study［J］. Lancet Oncol, 2010, 11(12): 1142-1148. ［29］ Lee J, Park SH, Chang HM, et al. Gemcitabine and oxaliplatin with or without erlotinib in advanced biliarytract cancer: a multicentre, openlabel, randomised, phase 3 study［J］. Lancet Oncol, 2012, 13(2): 181-188.

[1]	王俊毅, 洪楷彬, 纪荣佳, 陈大朝.癌结节对结直肠癌根治性切除术后肝转移的影响[J]. 国际肿瘤学杂志, 2024, 51(5): 280-285.
[2]	陈琦, 徐晨阳, 王寅, 雷大鹏.高光谱成像在头颈部肿瘤诊疗中的应用现状[J]. 国际肿瘤学杂志, 2024, 51(5): 298-302.
[3]	张栋岩, 王品, 魏秋亚, 邓成伍, 魏相相, 高远飞, 王琛.索凡替尼靶向联合卡培他滨和奥沙利铂治疗肝内胆管癌术后患者1例及文献复习[J]. 国际肿瘤学杂志, 2024, 51(4): 249-253.
[4]	张丽丽, 谭茹, 房雪利, 杨宇, 桑铮, 李宝生.乳腺导管原位癌影像学诊断、病理学升级及影像学技术进展[J]. 国际肿瘤学杂志, 2024, 51(3): 166-169.
[5]	孙国宝, 杨倩, 庄庆春, 高斌斌, 孙晓刚, 宋伟, 沙丹.结直肠癌肝转移组织病理学生长方式研究进展[J]. 国际肿瘤学杂志, 2024, 51(2): 114-118.
[6]	中国医师协会放射肿瘤治疗医师分会, 中华医学会放射肿瘤治疗学分会, 中国抗癌协会肿瘤放射治疗专业委员会.中国食管癌放射治疗指南（2023年版）[J]. 国际肿瘤学杂志, 2024, 51(1): 1-20.
[7]	黄辉, 丁江华.靶向FGFR2治疗晚期胆管癌的研究进展[J]. 国际肿瘤学杂志, 2023, 50(9): 569-573.
[8]	陈卓, 陶俊, 陈琳, 柯晶.外周血miR-194联合粪便miR-143检测对结直肠癌临床筛查的价值[J]. 国际肿瘤学杂志, 2023, 50(5): 268-273.
[9]	中国医师协会放射肿瘤治疗医师分会, 中华医学会放射肿瘤治疗学分会, 中国抗癌协会肿瘤放射治疗专业委员会.同步放化疗期间应用聚乙二醇化重组人粒细胞刺激因子中国专家共识（2023版）[J]. 国际肿瘤学杂志, 2023, 50(4): 193-201.
[10]	黎立喜, 张娣, 罗扬, 马飞.PARP抑制剂在乳腺癌中的临床应用[J]. 国际肿瘤学杂志, 2023, 50(2): 91-96.
[11]	陈郁, 许华, 刘海, 陈士新.基于CT影像学特征的恶性肺纯磨玻璃结节患者病理分型预测模型构建[J]. 国际肿瘤学杂志, 2023, 50(11): 655-660.
[12]	中国医师协会放射肿瘤治疗医师分会, 中华医学会放射肿瘤治疗学分会, 中国抗癌协会肿瘤放射治疗专业委员会.新型冠状病毒感染疫情背景下肿瘤患者放射治疗管理相关问题中国专家共识（2023版）[J]. 国际肿瘤学杂志, 2023, 50(10): 577-584.
[13]	高一钊, 刘洋, 刘秋龙, 邢金良.循环游离核酸在结直肠癌临床诊疗中的应用[J]. 国际肿瘤学杂志, 2022, 49(9): 555-559.
[14]	曾艳, 罗盼, 王子琪, 吴伟莉.药物在头颈部肿瘤治疗中引起铁死亡的作用机制[J]. 国际肿瘤学杂志, 2022, 49(3): 173-176.
[15]	中国医师协会放射肿瘤治疗医师分会, 中华医学会放射肿瘤治疗学分会, 中国抗癌协会肿瘤放射治疗专业委员会.中国头颈部肿瘤放射治疗指南(2021年版)[J]. 国际肿瘤学杂志, 2022, 49(2): 65-72.